CapsoVision, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CapsoVision, Inc. on September 22, 2025. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a new officer. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Saratoga, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Rebecca Petersen notified the Company of her planned retirement as Senior Director of Clinical Affairs, effective October 15, 2025.
- Appointment: Keri Jorgenson was promoted to Director of Clinical Operations. She will assume responsibility for clinical development operations and activities alongside the existing team.
- Transition Plan: The Company does not anticipate disruption to clinical development operations during this transition.
Guidance, Outlook, and Unusual Items
The filing contains no financial guidance, outlook, or discussion of risks and contingencies beyond the personnel transition. Regarding compensatory arrangements for the departing officer:
- Consulting Agreement: Ms. Petersen will provide consulting services starting October 16, 2025, at an hourly rate of $150.
- Termination: The agreement may be terminated by either party with three days' notice.
- Equity: Ms. Petersen's currently outstanding unvested employee stock options will continue to vest according to their existing schedule.
Key Facts for Investor Verification
- Verify the effective date of the leadership transition (October 15, 2025) and the start of the consulting arrangement (October 16, 2025).
- Confirm the total potential cost of the consulting agreement, noting the $150/hour rate and the lack of a fixed term in this summary.
- Review the upcoming Form 10-Q for the quarter ending September 30, 2025, for the complete text of the consulting agreement.
- Assess the impact of Ms. Petersen's departure on the Company's clinical development timeline, despite management's statement of no anticipated disruption.